STOP-HCV

We are an MRC-funded consortium exploring stratified medicine as an approach to treat patients with Hepatitis C.

[STOP-HCV @STOPHCV]

@JHepatology @NDMOxford @EleanorBarnesOx

[STOP-HCV @STOPHCV]

@JHepatology @NDMOxford Thank you @JHepatology. Our manuscript showing unusual HCV subtypes resistant to NS5A inhibitors. Lets not take our eye of this epidemic!

[Evelyne_Kestelyn @evelynekestelyn]

Enrolled the first participant into #VIETNARMS! A post-licensing trial of oral direct acting #antiviral #Hepatitis C treatment in #Vietnam incorporating a novel design with multiple arms. Amazing team work... @JeremyD_oucru @grahamscooke @ThuanDang8 @stat_sarah @barnaby_flower

[Graham Cooke @grahamscooke]

Interesting data emerging on potential role in SARS-CoV-2 of old HCV friends, sofosbuvir and daclatasvir. Some in vitro data https://t.co/7TtQ8Pg8rb with clinical studies underway in Iran and South Africa. Still desperate need for oral antivirals that can work in early infection

[COVID-HEP @CovidHep]

Wake up this morning to a new European registry for patients with COVID-19 and liver disease.
Data entry is quick and important.
Visit https://t.co/z53w5aBeMt

[COVID-HEP @CovidHep]

We are delighted to launch a European registry collecting data on patients with COVID-19 and chronic liver disease, cirrhosis, or liver transplantation (COVID-HEP). Please join the effort!
Report any case in less than 5-minutes at https://t.co/8CnUkrZYIF

[Emma Thomson @emcat1]

Implementation of new technologies in PHE labs, including NGS, highlighted as priorities in this strategy document from PHE

[STOP-HCV @STOPHCV]

Published alongside great work from @jacquesfellay team https://t.co/dnWVRmtVil

[STOP-HCV @STOPHCV]

Online now at @eLife, our work describing how interferon lambda 4 impacts the genetic diversity of hepatitis C virus https://t.co/qffu91RBqq @CVRinfo

[NIHR HPRU in Evaluation and Behavioural Science @HPRU_EBS]

Shortening direct-acting antiviral treatment in Genotype 1 noncirrhotic treatment-naive patients with mild chronic #hepatitis C is cost-effective (with proviso). See paper.
https://t.co/nr953gcT1I
@ISPORJournals @STOPHCV
#HCV #healtheconomics @NO_hep @HCVAction @hcvresearchnews

[STOP-HCV @STOPHCV]

Last stop-hcv meeting with the whole team. Six years of friendships and science. Lots of good works ongoing. Beautiful celebration cakes by emma hudson.

[NottmBRCLiver&GI @NottmBRCLiverGI]

Congratulations to Prof Will Irving for receiving the BASL Recognition of Service Award 2019 for his contributions made to Hepatitis C research! The award was presented to Will at the BASL Basic Science Retreat yesterday #hepatology @basl_events @NottmBRC @MedicineUoN @STOPHCV

[STOP-HCV @STOPHCV]

#BASL basic science in derbyshire. Will Irving gets recognition at EASL for being totally fabulous. So deserved.

[Evelyne_Kestelyn @evelynekestelyn]

Screening started for our pilot study to assess shortened therapy for #HCV infected adults in #Vietnam! #consentobtained #StopHepC @STOPHCV @grahamscooke @JeremyD_oucru @barnaby_flower @ThuanDang8

[STOP-HCV @STOPHCV]

No. Come combine data with stop-hcv for easl 2019.

[stephen barclay @stephentbarclay]

@aelsharkawy75 @GregDore2 @KirbyInstitute @JMPawlotsky Absolutely, would be delighted to recruit to that. Coincidentally I'm just looking at our NS5a failure retreatments. n=14, but includes a 1a vosevi failure treated with sof/g/p/RBV (outcome pending). Is n=14 worth the EASL abstract submission fee 🤔

[Ellie Barnes 🚵‍♀️ @EleanorBarnesOx]

Graham Cooke at NIHR senior investigator annual meeting showcasing the translation of recent HCV discoveries into clinical impact through his NIHR professorship. Studies in stratified medicine and treatment duration. Hugely important work. Watch this space.......

[STOP-HCV @STOPHCV]

Emma Thompson gives a super presentation about HCV subtypes in Africa. Multiple subtypes are likely resistant to sof/ledip. Careful treatment strategies required. #HCV #HCV2018

[Stuart Ray @soupvector]

The support of funding agencies like @NIH has been essential to what we've learned to date, and #HCV is particularly challenging due to its epidemiology and silence during acute infection. Vaccines are essential for ending epidemics, and cohorts are essential for HCV vaccine dev.

[STOP-HCV @STOPHCV]

#HCV2018 Josh Singer from CVR glasgow demonstrates HCV "super" GLUE in Dublin. Once you use it you'll stick with it forever. @emcat1

[Josh Singer @joshWentViral]

Excellent poster by David Smith at #HCV2018. A sophisticated methodology manages to identify a sofosbuvir-resistant polymorphism in NS2! @EleanorBarnesOx @STOPHCV